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1116-27 Mode of Death After Congenital Heart Surgery
Marsha Ma, Kimberlee Gauvreau, Catherine K. Allan, John E. Mayer, Kathy J. Jenkins, 
Children's Hospital Boston, Boston, MA
Background. Two thirds of deaths after adult coronary artery bypass surgery are due to
heart failure (O’Connor, 1998).
Method. To determine whether mode of death is the same or differs after congenital heart
surgery, we evaluated the mode of death for the most recent 100 deaths at our institution.
Mode of death was determined based on retrospective chart review including autopsy
reports when available and was assigned as the best understanding of the treating physi-
cians at the time of death. Patients who died of a low output state were further catego-
rized into pump failure (ventricular dysfunction); failed physiology (technically adequate
surgery and ventricular function, but persistent low output state); and pulmonary hyper-
tension (PAH). Additional variables indicative of pre- and post-operative status were also
evaluated.
Results. There was considerable anatomic diversity among patients who died; 44 cases
had single ventricle physiology. Most deaths occurred in infants; median age at surgery
15 days; median age at death 47 days. The vast majority of patients (79) were in the ICU
prior to the surgical procedure; 62 intubated, 52 intravenous inotropy, 49 prostaglandin, 6
nitric oxide, 12 hypoventilated, and 6 extracorporeal membrane oxygenation. Surgical
repairs were revised intraopertaively in 22 cases; 7 patients died in the operating room.
Of 100 deaths, 56 were due to low output: 29 failed physiology, 18 pump failure, 8 PAH,
and 1 other. Other causes of death included sudden cardiac arrest (11), sepsis (10), pro-
cedural complication (7), neurological injury (4), chronic lung disease (2), and other (10).
Among the 93 patients who survived to ICU: 48 had no known residual anatomical
defects, 44 had residual defects, and 1 unknown. Of these, 38 underwent additional sur-
gical (28) or catheter-based (10) procedures, although in some cases these procedures
were performed to treat mild residual defects in an attempt to rescue the patient from
death.
Conclusion. Mode of death after congenital heart surgery differs from adult cardiac sur-
gery. Over half of the deaths were due to low output state, but not to pump failure.
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1116-28 Importance of Systemic-to-Pulmonary Artery 
Collaterals in Pediatric Heart Transplant Recipients
Robert N. Vincent, William T. Mahle, Anthony A. Raviele, David K. Lawrence, Alexandria 
M. Berg, Children's Healthcare of Atlanta, Atlanta, GA, Emory University, Atlanta, GA
The presence of systemic-to-pulmonary collaterals (SPC) after the Fontan operation can
result in hemodynamic compromise, increased morbidity and mortality. METHODS: We
retrospectively reviewed our data on the occurrence of SPC and their relationship to mor-
bidity and mortality after heart transplantation (HT). Between July 1988 and Aug 2003,
we performed 152 transplant procedures. 73 transplants (48%) were performed for con-
genital heart defects(CHD); 51(34%) for idiopathic cardiomyopathy; 8(5%) for acquired
heart disease and 20(13%) were retransplant patients. Of the 73 patients with CHD,
50(70%) had single ventricular physiology of which 22(44%) had undergone a Fontan
procedure (Group 1), 11(22%) a Glenn anastomosis (Group 2) and 17(34%) were either
unoperated or had a palliative systemic to pulmonary artery shunt or pulmonary artery
band prior to transplant (Group 3).
RESULTS: Symptomatic SPC were found only in CHD patients with single ventricular
physiology. Symptoms varied from elevated left heart filling pressures and respiratory
compromise to acute graft failure and graft loss. 36% of both Group 1 and 2 patients had
occlusion of SPC after HT in comparison to 6% of Group 3. Occlusion was performed
using both Gianturco coils and polyvinyl alcohol embolization particles (350-500
microns). CONCLUSION: This data is consistent with previous observations that SPC’s
are a significant cause of morbidity and mortality (if not eliminated) after cavo-pulmonary
anastomosis and can also result in hemodynamic instability, heart failure and graft failure
post transplant. We conclude that patients with single ventricular physiology should have
assessment for and elimination of SPC’s pre-transplant if possible. Those who have
hemodynamic compromise post transplant should undergo careful reevaluation for SPC’s
and these should be eliminated if present.
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1116-29 Role of the Lipoxygenase-1 Receptor in Transducing 
the Apoptotic Signals of Circulating Atherogenic Low-
Density Lipoprotein
Jonathan Lu, Hsin-Hung Chen, Shinichi Suzuki, Chao-Yuh Yang, Philip D. Henry, Tatsuya 
Sawamura, Chu-Huang Chen, Baylor College of Medicine, Houston, TX, National 
Cardiovascular Research Institute, Osaka, Japan
Background:
LOX-1, a lectin-like receptor for oxidized LDL (oxLDL), is known to mediate various
effects of oxLDL produced in vitro. A highly electronegative subfraction of human plasma
LDL, designated L5, can inhibit fibroblast growth factor 2 (FGF2) transcription and induce
profound apoptosis in vascular endothelial cells (EC) in the absence of ex vivo oxidation.
To confirm the physiological significance of observations made with experimental oxLDL,
we examined the role of LOX-1 in the transduction of L5’s signals.
Methods:
LDL from hypercholesterolemic (HC; LDL-C > 160 mg/dL) human plasma analyzed by
ion exchange chromatography yielded five subfractions, L1–L5. Apoptotic signaling was
examined in bovine aortic EC (BAEC) exposed to L1–L5 in the presence or absence of
JTX20, a specific LOX-1 neutralizing antibody. 
Results:
In cultured BAEC, L5, but not L1–L4, induced apoptosis in a time- and concentration-
dependent manner. At 50 µg/mL, more than 50% of the cells exhibited DNA fragmenta-
tion and increased capase 3 activity at 24 hours. In the Bcl-2 family, Bcl-2 is antiapoptotic
while BAX is proapoptotic. In L5-treated BAEC, the mRNA and protein levels of Bcl-2
were reduced, whereas those of BAX were unchanged, resulting in a reduced Bcl-2/BAX
ratio. Supplementation of FGF2 prevented Bcl-2 downregulation and apoptosis. In con-
trast, vascular endothelial growth factor (VEGF), despite its mitogenic and antiapoptotic
properties resembling those of FGF2, was ineffective. As expected, FGF2 transcription
was inhibited in L5-treated cells. Interestingly, pretreatment of BAEC with JTX-20 attenu-
ated FGF2 and Bcl-2 downregulation in a concentration-dependent manner. At 20 µg/mL,
JTX-20 completely prevented FGF2 and Bcl-2 downregulation and apoptosis in L5-
exposed BAEC.
Conclusions: 
L5, a novel proapoptotic LDL subfraction, acts in part by downregulating FGF2 and Bcl-2.
These effects of L5 can be prevented by blockade of the LOX-1 receptor. Because EC
apoptosis contributes to the initiation and progression of atherosclerosis, our results
strongly indicate that the atherogenic effects of circulating electronegative LDL depends
on signaling through the LOX-1 receptor.
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1116-30 Effect of Apolipoprotein E, Gender, and Exercise on 
Lipase Activities
Richard L. Seip, Cherie Bilbie, Niall Moyna, Mary Miles, Robert F. Zoeller, Paul S. Visich, 
Theodore J. Angelopoulos, Linda Pescatello, Paul Gordon, Gregory Tsongalis, Linda 
Bausserman, Paul D. Thompson, Hartford Hospital, Hartford, CT
Introduction: Hepatic lipase (HLA) and lipoprotein lipase activities (LPLA) modify the
size and content of lipoproteins and also facilitate lipoprotein binding to hepatic recep-
tors. Some lipase functions are affected by apolipoprotein E (Apo E).
Methods: We investigated the effect of the common Apo E genotypes E2/3, E3/3, and
E4/3, on post heparin plasma lipase activities in n=53 E2/3, n=62 E3/3, and n=52 E4/3
healthy normolipidemic adults.
Results: As expected, HLA was 35% lower in women than in men (p<0.0001). Unex-
pected was a gender-specific Apo E genotype effect on HLA: HLA was higher in Apo E2/
3 men compared to E3/3 (p<0.05) and E4/3 men (p<0.01), but not in women. There were
no gender or Apo E effects on LPLA. A subgroup of 115 subjects exercised aerobically
for six months. HLA decreased 5.2% (p<0.018) with no Apo E effect on the change in
HLA. In contrast, the 3.1% increase (p=ns) in LPLA with exercise was Apo E dependent.
Apo E2 allele carriers increased LPLA more than Apo E3/3 subjects (p<0.05) after cor-
rection for the effects of age, insulin, baseline triglycerides, and baseline LPLA.
Conclusion: HLA is elevated in Apo E2/3 men, perhaps to compensate for slow clear-
ance of triglyceride-rich particles (chylomicrons and VLDL). The increase in LPLA with
exercise is greater in Apo E2/3 subjects than E3/3.
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1116-31 Induction of Marked Changes in Serum Lipids and 
Apolipoprotein A-1 Expression in Human Apo A-1 
Transgenic Mice by a Novel Peroxisome Proliferator-
Activated Receptor Alpha Agonist LY518674
Jai Pal Singh, Raymond Kauffman, Guoming Wang, Pam McClelland, William Bensch, 
Chahrzad Montrose, Chahrzad Montrose, Nathan Mantlo, Asavari Wagle, Eli Lilly and 
Company, Indianapolis, IN
Background: Low HDL cholesterol is a risk factor for heart disease. Fibrates are known
to reduce serum triglycerides and elevate HDL-cholesterol by modulating the activity of
nuclear hormone receptor PPARα. Fibrates are neither potent nor selective PPARα ago-
nists and their effects on HDL-cholesterol elevation in humans are generally small. A
more potent PPARa agonist would be a desirable therapy for lipid modification.
Method: Lipid modulating effects of a potent and selective PPARa agonist were studies
in human apoA-1 trasgenic mice. apo-1 expression was studies in primary monkey hepa-
tocytes.
Results: LY518674 was a potent (IC50 24 nM) and selective (310 fold selectivity over
PPARγ) PPARα agonist. In human apoA-1 transgenic mice, LY518674 produced a dose-
dependent increase in serum HDL-cholesterol resulting in 208+15% elevation at opti-
mum dose. New synthesis of apoA-1 was contributed to the increase in HDL-cholesterol.
In LY518674 treated animals, apoA-1 mRNA levels were significantly higher than the
controls. Liver slices from animals treated with LY518674 secreted 3-6 fold more apoA-1
then the untreated animals. In cultured hepatocytes, LY518674 produced 50% higher
apoA-1 secretion. The increase in apoA-1 secretion was associated with an increased
radiolabeled methionine incorporation in the apoA-1 protein.
Conclusion: LY518674 is a potent and selective PPARa agonist that produced a much
larger increase in serum HDL-cholesterol than the fibrates. The increase in HDL-choles-
terol was associated with a de novo synthesis of apoA-1.
